SI0719859T1 - Anti-alpha V-integrin monoclonal antibody - Google Patents

Anti-alpha V-integrin monoclonal antibody

Info

Publication number
SI0719859T1
SI0719859T1 SI9530683T SI9530683T SI0719859T1 SI 0719859 T1 SI0719859 T1 SI 0719859T1 SI 9530683 T SI9530683 T SI 9530683T SI 9530683 T SI9530683 T SI 9530683T SI 0719859 T1 SI0719859 T1 SI 0719859T1
Authority
SI
Slovenia
Prior art keywords
alpha
monoclonal antibody
integrin monoclonal
integrin
antibody
Prior art date
Application number
SI9530683T
Other languages
English (en)
Slovenian (sl)
Inventor
Francesc Mitjans
Jaume Adan
Jaume Piulats
Simon Goodman
Elisabet Rosell
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0719859(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI0719859T1 publication Critical patent/SI0719859T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI9530683T 1994-12-20 1995-12-06 Anti-alpha V-integrin monoclonal antibody SI0719859T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20
EP95119233A EP0719859B1 (en) 1994-12-20 1995-12-06 Anti-alpha V-integrin monoclonal antibody

Publications (1)

Publication Number Publication Date
SI0719859T1 true SI0719859T1 (en) 2003-12-31

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530683T SI0719859T1 (en) 1994-12-20 1995-12-06 Anti-alpha V-integrin monoclonal antibody

Country Status (26)

Country Link
US (1) US5985278A (sv)
EP (1) EP0719859B1 (sv)
JP (1) JP3898245B2 (sv)
KR (1) KR100450368B1 (sv)
CN (1) CN1117763C (sv)
AR (1) AR001778A1 (sv)
AT (1) ATE244306T1 (sv)
AU (1) AU710234B2 (sv)
BR (1) BR9505980B1 (sv)
CA (1) CA2165573C (sv)
CO (1) CO4480042A1 (sv)
CZ (1) CZ290477B6 (sv)
DE (1) DE69531187T2 (sv)
DK (1) DK0719859T3 (sv)
ES (1) ES2202336T3 (sv)
FI (1) FI118536B (sv)
HU (1) HU221061B1 (sv)
NO (1) NO321186B1 (sv)
PL (1) PL182961B1 (sv)
PT (1) PT719859E (sv)
RU (1) RU2205223C2 (sv)
SI (1) SI0719859T1 (sv)
SK (1) SK284932B6 (sv)
TR (1) TR199501614A2 (sv)
UA (1) UA40621C2 (sv)
ZA (1) ZA9510806B (sv)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009651A1 (fr) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
EP0846702B1 (en) * 1996-12-09 2009-03-11 MERCK PATENT GmbH Soluble recombinant alphaV beta3 adhesion receptor
PT1504764E (pt) * 1997-08-08 2009-01-14 Univ California Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6
ID27810A (id) * 1998-01-23 2001-04-26 Merck Patent Gmbh Antibodi menoclonal anti v-integrin dan kegunaan untuk mencegah penambahan v 6-integrin untuk fibronectin
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
JP4351043B2 (ja) 2001-07-09 2009-10-28 エラン ファーマシューティカルズ，インコーポレイテッド アミロイド毒性の阻害方法
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
NZ535425A (en) * 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
EP1492870A4 (en) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
CA2514653A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
NZ571068A (en) * 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
AU2007272995B2 (en) 2006-07-10 2013-02-07 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA3177366A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
JP5341889B2 (ja) * 2007-07-17 2013-11-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作された抗αＶインテグリンハイブリッド抗体
RU2490277C2 (ru) 2007-09-26 2013-08-20 Дженентек, Инк. Новые антитела
CN102265156B (zh) 2008-12-23 2014-11-05 默克专利有限公司 用于具有抗血管发生活性的抑制剂的生物标志
PE20120770A1 (es) 2009-03-25 2012-07-10 Genentech Inc ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
CA2780773A1 (en) 2009-11-13 2011-05-19 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
TR201810294T4 (tr) 2011-02-11 2018-08-27 Merck Patent Gmbh Prostat kanseri tedavisi için anti-alfa-v integrin antikoru.
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
KR102010098B1 (ko) * 2011-08-17 2019-08-13 더 리전트 오브 더 유니버시티 오브 캘리포니아 인테그린 알파-v 베타-8에 결합하는 항체
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10022453B2 (en) 2013-12-23 2018-07-17 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
MX2017003015A (es) 2014-09-17 2017-05-23 Merck Patent Gmbh Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.
MX2017003406A (es) 2014-09-17 2017-06-19 Merck Patent Gmbh Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
MX2017017172A (es) 2015-06-22 2018-02-23 Bayer Pharma AG Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
RU2018102358A (ru) 2015-06-23 2019-07-25 Байер Фарма Акциенгезельшафт Нацеленные конъюгаты ksp ингибиторов
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
RU2018136778A (ru) 2016-03-24 2020-04-24 Байер Фарма Акциенгезельшафт Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
BR112019012883A2 (pt) 2016-12-21 2019-11-26 Bayer Ag conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
CA3116669A1 (en) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
KR20220005471A (ko) * 2019-04-08 2022-01-13 바이오젠 엠에이 인코포레이티드 항-인테그린 항체 및 이의 용도
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680411B2 (en) * 1992-04-03 1997-07-31 Genentech Inc. Antibodies to alphavbeta3 integrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
FI956112A (sv) 1996-06-21
CA2165573C (en) 2011-03-29
NO955167D0 (no) 1995-12-19
EP0719859A1 (en) 1996-07-03
KR960022562A (ko) 1996-07-18
CO4480042A1 (es) 1997-07-09
PT719859E (pt) 2003-11-28
SK159295A3 (en) 1996-07-03
UA40621C2 (uk) 2001-08-15
NO321186B1 (no) 2006-04-03
ZA9510806B (en) 1996-05-30
JPH08231597A (ja) 1996-09-10
SK284932B6 (sk) 2006-02-02
HU9503638D0 (en) 1996-02-28
EP0719859B1 (en) 2003-07-02
HU221061B1 (hu) 2002-07-29
PL311926A1 (en) 1996-06-24
US5985278A (en) 1999-11-16
DK0719859T3 (da) 2003-10-20
FI956112A0 (sv) 1995-12-19
DE69531187T2 (de) 2004-04-22
JP3898245B2 (ja) 2007-03-28
CZ290477B6 (cs) 2002-07-17
ATE244306T1 (de) 2003-07-15
BR9505980B1 (pt) 2010-02-23
BR9505980A (pt) 1997-12-23
CN1117763C (zh) 2003-08-13
TR199501614A2 (tr) 1996-07-21
FI118536B (sv) 2007-12-14
ES2202336T3 (es) 2004-04-01
RU2205223C2 (ru) 2003-05-27
AR001778A1 (es) 1997-12-10
CZ328895A3 (en) 1996-09-11
NO955167L (no) 1996-06-21
PL182961B1 (pl) 2002-05-31
CN1139115A (zh) 1997-01-01
CA2165573A1 (en) 1996-06-21
DE69531187D1 (de) 2003-08-07
HUT74828A (en) 1997-02-28
AU4042195A (en) 1996-06-27
AU710234B2 (en) 1999-09-16
KR100450368B1 (ko) 2005-01-31

Similar Documents

Publication Publication Date Title
SI0719859T1 (en) Anti-alpha V-integrin monoclonal antibody
IL128406A0 (en) Monoclonal antibodies
GB9422383D0 (en) Antibodies
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
GB9412166D0 (en) Retargetting antibodies
EP0580859A4 (en) Anti-eda monoclonal antibody
ZA973664B (en) Hepatitis b monoclonal antibodies
EP0909278A4 (en) IMMUNOGLOBULIN G LINKED TO NEPHROPATHY AND ANTIBODIES AGAINST IT
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AP9801381A0 (en) Anti-human mp52 monoclonal antibody
GB9615027D0 (en) Monoclonal antibodies
GB9212074D0 (en) Monoclonal antibody
SG64332A1 (en) Monoclonal antibody
ZA954678B (en) Monoclonal antibody against cd44v6
GB9415331D0 (en) Antibodies
GB9406222D0 (en) Huminised antibodies
GB9406243D0 (en) Antibodies
IL134049A0 (en) Anti-cryptdin antibodies
GB9401597D0 (en) Altered antibodies
GB9406244D0 (en) Altered antibodies
GB9320508D0 (en) Antibodies
GB9309884D0 (en) Antibodies